Clinical trials: Environmental Exposures
- Condition Environmental Exposures
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Rhinitis, Allergic, Seasonal
Compare the Efficacy of Levocetirizine and Montelukast to Placebo in Reducing Seasonal Allergic Rhinitis (SAR) Symptoms in Ragweed Sensitive Subjects
To compare the clinical efficacy of levocetirizine 5 mg and montelukast 10 mg on symptoms of seasonal allergic rhinitis occurring in subjects exposed to ragweed pollen in an environmental exposure unit.
- Trial name
- NCT00295022
- Testing
- Montelukast, Levocetirizine
- Where
- Canada
- Volunteers
- 418 people
- Sponsor
- UCB S.A. - Pharma Sector
Dry Eye Syndromes
Evaluation of the Safety and Effectiveness of the Oculeve Intranasal Lacrimal Neurostimulator in Patients With Dry Eye
The purpose of this study was to evaluate the safety and effectiveness of the Intranasal Tear Neurostimulator applied intranasally compared with the same device applied extranasally (control) in treating the symptoms of dry eye…
- Trial name
- NCT02313454
- Testing
- Intranasal Tear Neurostimulator
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Allergan
Allergic Rhinitis Due to House Dust Mite
Efficacy and Safety of 100IR, 300IR, 500IR Sublingual House Dust Mite Tablets in Allergic Rhinitis Environment Exposure Chamber Model
The purpose of this study is to assess the effect of 3 doses of sublingual house dust mite (HDM) tablets versus placebo in the change from baseline of rhinitis total symptom score during the allergen chamber challenge before and…
- Trial name
- NCT01527188
- Testing
- 100 IR house dust mites allergen extract tablet, 300 IR house dust mites allergen extract tablet, 500 IR house dust mites allergen extract tablet
- Where
- Canada
- Volunteers
- 355 people
- Sponsor
- Stallergenes Greer
Nasal Allergies, Allergies
Safety and Efficacy of AL-53817 Nasal Spray Solution
The purpose of this study was to determine the maximum tolerated dose of AL-53817 (Stage A) and evaluate the safety and efficacy of AL-53817 for the treatment of allergic rhinitis (Stage B).
- Trial name
- NCT01454505
- Testing
- AL-53817 nasal spray solution, Vehicle nasal spray
- Where
- United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Alcon Research
Rhinitis, Allergic
A Study to Compare the Efficacy of Levocetirizine to Placebo in Reducing Symptoms of Seasonal Allergic Rhinitis (SAR) in Sensitive Subjects Exposed to Ragweed Pollen
The purpose of the study is to assess the efficacy comparability of cetirizine and levocetirizine, by comparing the effects of single intake of the two drugs to placebo in reducing symptoms of seasonal allergic rhinitis (SAR) in…
- Conditions
- Rhinitis, Allergic, Seasonal
- Trial name
- NCT00291642
- Testing
- Levocetirizine drops, Levocetirizine tablets
- Where
- Canada
- Volunteers
- 551 people
- Sponsor
- UCB Pharma
Allergic Conjunctivitis
The INVIGORATE Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis.
The INVIGORATE Trial: A Randomized, Double-masked, Crossover Design, Phase 3 Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis.
- Trial name
- NCT04207736
- Testing
- Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic Solution
- Where
- Canada
- Volunteers
- 95 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Environmental Exposure
Real-Life Passive Exposure Assessment of IQOS
This study is a non-interventional observational study designed to assess the impact of passive exposure to IQOS environmental tobacco aerosol in Non-Smokers in a real-life restaurant setting.
- Trial name
- NCT03550989
- Testing
- Non-Exposure Event, Exposure Event
- Where
- Japan
- Volunteers
- 401 people, healthy volunteers welcome
- Sponsor
- Philip Morris Products S.A.
Seasonal Allergic Rhinitis
This Study Contains an Active Drug Treatment Group With Mometasone Furoate Nasal Spray and a Placebo (Dummy) Treatment Group for Seasonal Allergic Rhinitis (SAR). (Study P05073)(COMPLETED)
The purpose of this study is to evaluate how well mometasone furoate nasal spray (MFNS) works to relieve SAR symptoms compared to Placebo when symptoms are induced in a chamber setting.
- Trial name
- NCT00491504
- Testing
- Mometasone Furoate Nasal Spray
- Volunteers
- 310 people
- Sponsor
- Organon and Co
Dry Eye Syndromes
Evaluation of Dry Eye Symptoms in CAE With Application of Intranasal Neurostimulation
This study evaluates the safety and effectiveness of the Intranasal Tear Neurostimulator applied intranasally (active) compared with the same device applied extranasally (control) relating to symptoms of dry eye exacerbated by…
- Trial name
- NCT02910713
- Testing
- Intranasal Tear Neurostimulator
- Where
- 3 sites in United States
- Volunteers
- 185 people
- Sponsor
- Allergan
Seasonal Allergic Rhinitis
Safety, Pharmacokinetics, and Efficacy of Bepotastine Besilate Nasal Product After Ragweed Pollen Exposure in an Environmental Chamber
The purpose of this study is to examine the safety and efficacy of bepotastine besilate nasal product in seasonal allergic rhinitis patients.
- Trial name
- NCT01222299
- Testing
- bepotastine besilate nasal product - low dose, bepotastine besilate nasal product - medium dose, bepotastine besilate nasal product - high dose
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- Bausch & Lomb Incorporated
Conjunctivitis, Allergic
A Methodology Development Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis Using the Environmental Exposure Chamber
An Exploratory Clinical Trial Evaluating Reproxalap Ophthalmic Solutions (0.25% and 0.5%) in Subjects with Seasonal Allergic Conjunctivitis Using the Environmental Exposure Chamber (EEC)
- Trial name
- NCT03709121
- Testing
- Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalmic Solution (0.5%), Vehicle Ophthalmic Solution
- Where
- Canada
- Volunteers
- 70 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Allergic Conjunctivitis
The INVIGORATE 2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis
The INVIGORATE 2 Trial: A single-center, randomized, double-masked, crossover design, vehicle-controlled, Phase 3 clinical trial to assess the efficacy and safety of reproxalap ophthalmic solution (0.25%) compared to vehicle in…
- Trial name
- NCT05234554
- Testing
- Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic Solution
- Where
- Canada
- Volunteers
- 131 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Effect of Game in Increasing Environmental Health Literacy
Evaluation of Prototype for Simulation for Environmental Exposure Education (SE3)
The goal of this clinical trial is to test a prototype of a new educational game about environmental health literacy with middle school age youth.
- Trial name
- SE3 (NCT05875467)
- Testing
- SE3 Game
- Where
- 2 sites in United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- dfusion Inc
Allergic Conjunctivitis
Safety and Efficacy Study of AL-53817 and AL-78843 Ophthalmic Solutions for Allergic Conjunctivitis
The purpose of this study is to evaluate two investigational ophthalmic solutions for reduction in ocular redness in subjects with allergic conjunctivitis.
- Trial name
- NCT02079649
- Testing
- AL-53817 Ophthalmic Solution, 0.1%, AL-78843 Ophthalmic Solution, 0.03%, Dexamethasone Ophthalmic Suspension, 0.1%
- Volunteers
- 224 people
- Sponsor
- Alcon Research
Endocrine Disrupting Chemicals, Environmental Exposure
Personalized Mobile Intervention to Reduce Exposure to Endocrine Disrupting Chemicals in Adults of Child-Bearing Age
The goal of this intervention study is to determine to what extent the Million Marker (MM) program reduces users' endocrine disruption chemical (EDC) exposure levels and changes their environmental health awareness and behaviors.
- Conditions
- Endocrine Disrupting Chemicals, Environmental Exposure, Health Literacy, Bisphenol A
- Trial name
- NCT05780047
- Testing
- Mail-in Urine Test for EDCs
- Where
- United States
- Volunteers
- 434 people, healthy volunteers welcome
- Sponsor
- Million Marker Wellness, Inc.
Rhinitis, Allergic, Perennial, Rhinitis, Allergic, Nonseasonal
A Dose-Ranging Study of the Safety and Effectiveness of MK-8237 in the Treatment of House Dust Mite (HDM) Induced Allergic Rhinitis/Rhinoconjunctivitis in Adults (MK-8237-003/P07627)
The purpose of this study is to evaluate the dose-related effectiveness, the safety and the tolerability of MK-8237, compared to placebo, in the treatment of house dust mite (HDM)-induced allergic rhinitis/rhinoconjunctivitis in…
- Trial name
- NCT01644617
- Testing
- MK-8237 6 DU, MK-8237 12 DU
- Volunteers
- 124 people
- Sponsor
- ALK-Abelló A/S
Allergic Conjunctivitis
Assessment of Alcon's Ocular Image Quantification System
The purpose of this study was to evaluate ocular responses with different allergen provocation methods.
- Trial name
- NCT01282138
- Testing
- Olopatadine hydrochloride, 0.1% ophthalmic solution (Patanol), Dextran 70 0.1%, hydroxypropyl methylcellulose 0.3% (Tears Naturale II)
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Alcon Research
Asthma
A Study of Omalizumab in Preventing Bronchoconstriction Following Environmental Cat Dander Exposure in Patients With Cat Dander-induced Asthma
This was a 3-center, randomized, double-blind, parallel-group, placebo-controlled study with a 16-week treatment phase to determine whether subcutaneous omalizumab, compared with placebo, reduces the degree of bronchoconstriction…
- Trial name
- AERO (NCT00495612)
- Testing
- Omalizumab
- Volunteers
- 69 people
- Sponsor
- Genentech, Inc.
Skin Cancer, Occupational Exposure
Virtual Sun Safe Workplaces Ph II (SSW Works)
Americans who work outdoors are exposed to an extreme amount of solar ultraviolet radiation over a lifetime that substantially increases their risk for developing skin cancer.
- Trial name
- NCT05774600
- Testing
- SSW Works, Minimal Information Control
- Where
- United States
- Volunteers
- 543 people, healthy volunteers welcome
- Sponsor
- Klein Buendel, Inc.
Seasonal Allergic Rhinitis
Dymista Allergen Chamber - Onset of Action Study
This study is to assess the onset of action of fixed drug combination of azelastine hydrochloride and fluticasone propionate nasal spray (Dymista) in treating the nasal symptoms of seasonal allergic rhinitis (SAR) induced by an…
- Trial name
- NCT04652245
- Testing
- Treatment A (Dymista): Fixed drug combination of azelastine hydrochloride and fluticasone propionate nasal spray at Visit 3, Treatment A (Dymista): Fixed drug combination of azelastine hydrochloride and fluticasone propionate nasal spray at Visit 5
- Where
- Canada
- Volunteers
- 216 people
- Sponsor
- MEDA Pharma GmbH & Co. KG